{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T16:34:55Z","timestamp":1791304495231,"version":"4.3.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2009,3,22]],"date-time":"2009-03-22T00:00:00Z","timestamp":1237680000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Rheumatol Rep"],"published-print":{"date-parts":[[2009,4]]},"DOI":"10.1007\/s11926-009-0019-z","type":"journal-article","created":{"date-parts":[[2009,3,21]],"date-time":"2009-03-21T12:35:07Z","timestamp":1237638907000},"page":"135-140","source":"Crossref","is-referenced-by-count":94,"title":["A critical reappraisal of allopurinol dosing, safety, and efficacy for hyperuricemia in gout"],"prefix":"10.1007","volume":"11","author":[{"given":"Jeannie","family":"Chao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Terkeltaub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,3,22]]},"reference":[{"key":"19_CR1","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.1002\/art.20438","volume":"50","author":"J.D. Bieber","year":"2004","unstructured":"Bieber JD, Terkeltaub RA: Gout: on the brink of novel therapeutic options for an ancient disease. Arthritis Rheum 2004, 50:2400\u20132414.","journal-title":"Arthritis Rheum"},{"key":"19_CR2","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1002\/art.23803","volume":"58","author":"N.L. Edwards","year":"2008","unstructured":"Edwards NL: Treatment-failure gout: a moving target. Arthritis Rheum 2008, 58:2587\u20132590.","journal-title":"Arthritis Rheum"},{"key":"19_CR3","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1002\/art.24201","volume":"59","author":"J.S. Sundy","year":"2008","unstructured":"Sundy JS: Gout management: let\u2019s get it right this time. Arthritis Rheum 2008, 59:1535\u20131537.","journal-title":"Arthritis Rheum"},{"key":"19_CR4","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1136\/ard.2006.055269","volume":"65","author":"W. Zhang","year":"2006","unstructured":"Zhang W, Doherty M, Bardin T, et al.: EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006, 65:1312\u20131324.","journal-title":"Ann Rheum Dis"},{"key":"19_CR5","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1056\/NEJMoa050373","volume":"353","author":"M.A. Becker","year":"2005","unstructured":"Becker MA, Schumacher HR Jr, Wortmann RL, et al.: Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005, 353:2450\u20132461.","journal-title":"N Engl J Med"},{"key":"19_CR6","unstructured":"US National Library of Medicine DailyMed: FDA information: allopurinol tablet. Available at http:\/\/dailymed.nlm.nih.gov\/dailymed\/search.cfm?startswith=allopurinol . Accessed February 2009."},{"key":"19_CR7","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1093\/rheumatology\/kem056a","volume":"46","author":"K.M. Jordan","year":"2007","unstructured":"Jordan KM, Cameron JS, Snaith M, et al.: British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. Rheumatology (Oxford) 2007, 46:1372\u20131374.","journal-title":"Rheumatology (Oxford)"},{"key":"19_CR8","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/01.rhu.0000164822.98163.22","volume":"11","author":"F. Perez-Ruiz","year":"2005","unstructured":"Perez-Ruiz F, Hernando I, Villar I, Nolla JM: Correction of allopurinol dosing should be based on clearance of creatinine, but not plasma creatinine levels: another insight to allopurinol-related toxicity. J Clin Rheumatol 2005, 11:129\u2013133.","journal-title":"J Clin Rheumatol"},{"key":"19_CR9","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1136\/ard.57.9.545","volume":"57","author":"F. Perez-Ruiz","year":"1998","unstructured":"Perez-Ruiz F, Alonso-Ruiz A, Calabozo M, et al.: Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout. Ann Rheum Dis 1998, 57:545\u2013549.","journal-title":"Ann Rheum Dis"},{"key":"19_CR10","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0002-9343(84)90743-5","volume":"76","author":"K.R. Hande","year":"1984","unstructured":"Hande KR, Noone RM, Stone WJ: Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med 1984, 76:47\u201356.","journal-title":"Am J Med"},{"key":"19_CR11","doi-asserted-by":"crossref","first-page":"925","DOI":"10.4065\/81.7.925","volume":"81","author":"C.A. Sarawate","year":"2006","unstructured":"Sarawate CA, Brewer KK, Yang W, et al.: Gout medication treatment patterns and adherence to standards of care from a managed care perspective. Mayo Clin Proc 2006, 81:925\u2013934.","journal-title":"Mayo Clin Proc"},{"key":"19_CR12","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1016\/j.jacc.2008.01.068","volume":"51","author":"J.M. Hare","year":"2008","unstructured":"Hare JM, Mangal B, Brown J, et al.: Impact of oxypurinol in patients with symptomatic heart failure. Results of the OPT-CHF study. J Am Coll Cardiol 2008, 51:2301\u20132309.","journal-title":"J Am Coll Cardiol"},{"key":"19_CR13","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1001\/jama.300.8.924","volume":"300","author":"D.I. Feig","year":"2008","unstructured":"Feig DI, Soletsky B, Johnson RJ: Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. JAMA 2008, 300:924\u2013932.","journal-title":"JAMA"},{"key":"19_CR14","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1056\/NEJMra0800885","volume":"359","author":"D.I. Feig","year":"2008","unstructured":"Feig DI, Kang DH, Johnson RJ: Uric acid and cardiovascular risk. N Engl J Med 2008, 359:1811\u20131821.","journal-title":"N Engl J Med"},{"key":"19_CR15","doi-asserted-by":"crossref","first-page":"21","DOI":"10.6032\/gnam1999.25.1_21","volume":"25","author":"M. Kiyonobu","year":"2001","unstructured":"Kiyonobu M, Hisashi Y, Naoyuki K, et al.: Retrospective analysis of liver toxicity due to anti-hyperuricemic drugs in Japan. Gout Nucleic Acid Metabol 2001, 25:21\u201327.","journal-title":"Gout Nucleic Acid Metabol"},{"key":"19_CR16","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/0002-9343(89)90316-1","volume":"86","author":"S. Tam","year":"1989","unstructured":"Tam S, Carroll W: Allopurinol hepatotoxicity. Am J Med 1989, 86:357\u2013358.","journal-title":"Am J Med"},{"key":"19_CR17","doi-asserted-by":"crossref","first-page":"588","DOI":"10.7326\/0003-4819-95-5-588","volume":"95","author":"F.H. Al-Kawas","year":"1981","unstructured":"Al-Kawas FH, Seeff LB, Berendson RA, et al.: Allopurinol hepatotoxicity. Report of two cases and review of the literature. Ann Intern Med 1981, 95:588\u2013590.","journal-title":"Ann Intern Med"},{"key":"19_CR18","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1002\/art.1780200817","volume":"20","author":"S.K. Chawla","year":"1977","unstructured":"Chawla SK, Patel HD, Parrino GR, et al.: Allopurinol hepatotoxicity. Case report and literature review. Arthritis Rheum 1977, 20:1546\u20131549.","journal-title":"Arthritis Rheum"},{"key":"19_CR19","first-page":"385","volume":"49","author":"H.Y. Lee","year":"2008","unstructured":"Lee HY, Ariyasinghe JT, Thirumoorthy T: Allopurinol hypersensitivity syndrome: a preventable severe cutaneous reaction? Singapore Med J 2008, 49:385\u2013387.","journal-title":"Singapore Med J"},{"key":"19_CR20","unstructured":"Khanna D, Fuldeore MJ, Meissner BL, et al.: The incidence of allopurinol hypersensitivity syndrome: a population perspective. Presented at the Annual American College of Rheumatology Scientific Meeting (ACR\/ARHP) Poster Session C. San Francisco, CA; October 23\u201328, 2008:S672."},{"key":"19_CR21","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1073\/pnas.0409500102","volume":"102","author":"S.I. Hung","year":"2005","unstructured":"Hung SI, Chung WH, Liou LB, et al.: HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci USA 2005, 102:4134\u20134139.","journal-title":"Proc Natl Acad Sci USA"},{"key":"19_CR22","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/FPC.0b013e3282f3ef9c","volume":"18","author":"C. Lonjou","year":"2008","unstructured":"Lonjou C, Borot N, Sekula P, et al.: A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet Genomics 2008, 18:99\u2013107.","journal-title":"Pharmacogenet Genomics"},{"key":"19_CR23","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1159\/000102045","volume":"215","author":"T. Dainichi","year":"2007","unstructured":"Dainichi T, Uchi H, Moroi Y, Furue M: Stevens-Johnson syndrome, drug-induced hypersensitivity syndrome and toxic epidermal necrolysis caused by allopurinol in patients with a common HLA allele: what causes the diversity? Dermatology 2007, 215:86\u201388.","journal-title":"Dermatology"},{"key":"19_CR24","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1002\/art.1780310318","volume":"31","author":"B.T. Emmerson","year":"1988","unstructured":"Emmerson BT, Hazelton RA, Frazer IH: Some adverse reactions to allopurinol may be mediated by lymphocyte reactivity to oxypurinol. Arthritis Rheum 1988, 31:436\u2013440.","journal-title":"Arthritis Rheum"},{"key":"19_CR25","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1006\/clin.1994.1022","volume":"70","author":"G.L. Braden","year":"1994","unstructured":"Braden GL, Warzynski MJ, Golightly M, et al.: Cell-mediated immunity in allopurinol-induced hypersensitivity. Clin Immunol Immunopathol 1994, 70:145\u2013151.","journal-title":"Clin Immunol Immunopathol"},{"key":"19_CR26","first-page":"1646","volume":"33","author":"N. Dalbeth","year":"2006","unstructured":"Dalbeth N, Kumar S, Stamp L, Gow P: Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout. J Rheumatol 2006, 33:1646\u20131650.","journal-title":"J Rheumatol"},{"key":"19_CR27","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/j.1525-139X.2007.00270.x","volume":"20","author":"N. Dalbeth","year":"2007","unstructured":"Dalbeth N, Stamp L: Allopurinol dosing in renal impairment: walking the tightrope between adequate urate lowering and adverse events. Sem Dial 2007, 20:391\u2013395.","journal-title":"Sem Dial"},{"key":"19_CR28","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1136\/ard.60.10.981","volume":"60","author":"J. Vazquez-Mellado","year":"2001","unstructured":"Vazquez-Mellado J, Morales EM, Tena CP, et al.: Relation between adverse events associated with allopurinol and renal function in patients with gout. Ann Rheum Dis 2001, 60:981\u2013989.","journal-title":"Ann Rheum Dis"},{"key":"19_CR29","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1097\/RHU.0b013e318164dceb","volume":"14","author":"D. Panomvana","year":"2008","unstructured":"Panomvana D, Sripradit S, Angthararak S: Higher therapeutic plasma oxypurinol concentrations might be required for gouty patients with chronic kidney disease. J Clin Rheumatol 2008, 14:6\u201311.","journal-title":"J Clin Rheumatol"},{"key":"19_CR30","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1002\/art.23007","volume":"57","author":"F. Perez-Ruiz","year":"2007","unstructured":"Perez-Ruiz F, Liot\u00e9 F: Lowering serum uric acid levels: what is the optimal target for improving clinical outcomes in gout? Arthritis Rheum 2007, 57:1324\u20131328.","journal-title":"Arthritis Rheum"},{"key":"19_CR31","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1159\/000045783","volume":"86","author":"F. Perez-Ruiz","year":"2000","unstructured":"Perez-Ruiz F, Calabozo M, Herrero-Beites AM, et al.: Improvement of renal function in patients with chronic gout after proper control of hyperuricemia and gouty bouts. Nephron 2000, 86:287\u2013291.","journal-title":"Nephron"},{"key":"19_CR32","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1053\/j.ajkd.2005.10.006","volume":"47","author":"Y.P. Siu","year":"2006","unstructured":"Siu YP, Leung KT, Tong MK, Kwan TH: Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis 2006, 47:51\u201359.","journal-title":"Am J Kidney Dis"},{"key":"19_CR33","doi-asserted-by":"crossref","unstructured":"Reinders MK, Haagsma C, Jansen TL, et al.: A randomized controlled trial on the efficacy and tolerability with dose-escalation of allopurinol 300\u2013600 mg\/day versus benzbromarone 100\u2013200 mg\/day in patients with gout. Ann Rheum Dis 2008 Jul 16 (Epub ahead of print).","DOI":"10.1136\/ard.2007.083071"},{"key":"19_CR34","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1002\/art.24209","volume":"59","author":"H.R. Schumacher Jr","year":"2008","unstructured":"Schumacher HR Jr, Becker MA, Wortmann RL, et al.: Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum 2008, 59:1540\u20131548.","journal-title":"Arthritis Rheum"},{"key":"19_CR35","unstructured":"Becker M, Schumacher HR Jr, Espinoza L, et al.: A phase 3 randomized, controlled, multicenter, double-blind trial (RCT) comparing efficacy and safety of daily febuxostat (FEB) and allopurinol (ALLO) in subjects with gout [abstract L11]. Presented at the Annual American College of Rheumatology Scientific Meeting Concurrent Session. San Francisco, CA: October 13\u201328, 2008."},{"key":"19_CR36","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/S0024-3205(00)00532-4","volume":"66","author":"H. Horiuchi","year":"2000","unstructured":"Horiuchi H, Ota M, Nishimura S, et al.: Allopurinol induces renal toxicity by impairing pyrimidine metabolism in mice. Life Sci 2000, 66:2051\u20132070.","journal-title":"Life Sci"}],"container-title":["Current Rheumatology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-009-0019-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11926-009-0019-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-009-0019-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T00:49:51Z","timestamp":1559436591000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11926-009-0019-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,3,22]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,4]]}},"alternative-id":["19"],"URL":"https:\/\/doi.org\/10.1007\/s11926-009-0019-z","relation":{},"ISSN":["1523-3774","1534-6307"],"issn-type":[{"value":"1523-3774","type":"print"},{"value":"1534-6307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,3,22]]}}}